Genedx Holdings Corp (WGS) Stock Price, Quote & News

Company Profile

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 888 729 1206

Fax: 201 421 2010

Website: www.genedx.com

Address:

North Tower, 6th Floor 333 Ludlow Street, Stamford, United States

Badinvestor50 Jul. 2 at 5:10 PM

$WGS down 5% on 360k in volume what a joke

0 · Reply

CarverX Jul. 1 at 8:11 PM

$WGS $TEM Good moves today in gene diagnostics 🚀🚀🚀

0 · Reply

11thestate Jun. 30 at 2:08 PM

If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $WGS how you can actually recover something:https://11th.com/cases/cmls-investor-settlement

0 · Reply

Buckanator Jun. 29 at 6:00 PM

$WGS I sold today at $68.95, Great trade, more than doubled my money.

2 · Reply

CarverX Jun. 29 at 5:04 PM

$WGS Probably 60s range bound til earnings

0 · Reply

Badinvestor50 Jun. 26 at 6:41 PM

$BSX $WGS well I jinxed these two that’s for sure

0 · Reply

Badinvestor50 Jun. 26 at 4:25 PM

$BSX rip missing $45. It’s alright this is going to move back like $WGS soon

0 · Reply

PencilNeckGeek Jun. 26 at 2:17 PM

$WGS Impressive how strong this has been

0 · Reply

CarverX Jun. 25 at 7:47 PM

$WGS Lots of insider purchases to buffet the sp and get the shyster lawyersboff our backs. Time for Stue to step up or time for Meister to get rid of her🚀🚀🚀

0 · Reply

PencilNeckGeek Jun. 25 at 7:26 PM

$WGS Pretty amazing strength this has shown recently

0 · Reply

WGS Stockholders Have Rights – If You Lost Money Investing in GeneDx Holdings Corp. Contact Robbins LLP for Information About Recovering Your Losses

2026-06-29T11:05:43.000Z - 5 days ago

GeneDx price target raised to $74 from $70 at Guggenheim

2026-06-23T11:03:08.000Z - 11 days ago

GeneDx price target raised to $63 from $50 at Piper Sandler

Jun 18, 2026, 9:00 AM EDT - 16 days ago

GeneDx Holdings Transcript: AGM 2026

2026-06-16T12:38:10.000Z - 18 days ago

GeneDx appoints Gardner as President

Jun 16, 2026, 8:30 AM EDT - 18 days ago

GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth

Jun 15, 2026, 9:30 AM EDT - 19 days ago

Investor Notice of Barrack, Rodos & Bacine Concerning Its Lawsuit Against GeneDx Holdings Corp. (WGS)

Jun 11, 2026, 9:00 AM EDT - 23 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS

Jun 10, 2026, 9:47 AM EDT - 24 days ago

GENEDX HOLDINGS CORP. (WGS) INVESTOR ALERT Investors With Large Losses in GeneDe Holdings Corp. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 10, 2026, 8:27 AM EDT - 24 days ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of GeneDx Holdings Corp. (WGS)

Jun 9, 2026, 8:00 AM EDT - 25 days ago

GeneDx Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 3:30 PM EDT - 4 weeks ago

GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSS

May 26, 2026, 4:05 PM EDT - 5 weeks ago

GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026, 9:30 AM EDT - 6 weeks ago

Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud

2026-05-05T12:38:23.000Z - 2 months ago

GeneDx price target lowered to $85 from $153 at Craig-Hallum

May 5, 2026, 8:09 AM EDT - 2 months ago

GeneDx Holdings Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-05-05T12:02:38.000Z - 2 months ago

GeneDx price target lowered to $55 from $60 at TD Cowen

2026-05-05T11:43:37.000Z - 2 months ago

GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks

2026-05-05T11:27:49.000Z - 2 months ago

GeneDx price target lowered to $70 from $100 at Guggenheim

2026-05-05T10:25:04.000Z - 2 months ago

GeneDx price target lowered to $75 from $155 at Wells Fargo

2026-05-04T20:32:20.000Z - 2 months ago

GeneDx reports Q1 adjusted loss ($8.2M) vs. ($9.2M) last year

May 4, 2026, 4:30 PM EDT - 2 months ago

GeneDx Holdings Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

GeneDx Holdings Slides: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

GeneDx Holdings Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

GeneDx Holdings Quarterly report: Q1 2026

May 4, 2026, 4:05 PM EDT - 2 months ago

GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook

Apr 30, 2026, 8:00 AM EDT - 2 months ago

GeneDx Holdings Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

GeneDx Holdings Proxy statement: Proxy filing

2026-04-20T13:59:20.000Z - 2 months ago

GeneDx price target raised to $100 from $70 at Canaccord

Apr 13, 2026, 4:05 PM EDT - 2 months ago

GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026

2026-04-10T04:42:30.000Z - 3 months ago

Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside

ARCT ARKG ARKK BWXT SRTA

2026-03-30T11:51:54.000Z - 3 months ago

GeneDx price target lowered to $100 from $170 at Guggenheim

Mar 11, 2026, 5:00 PM EDT - 4 months ago

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

Mar 11, 2026, 3:00 PM EDT - 4 months ago

GeneDx Holdings Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:30 AM EDT - 4 months ago

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Mar 9, 2026, 8:30 AM EDT - 4 months ago

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

Feb 25, 2026, 8:03 PM EST - 4 months ago

HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Feb 25, 2026, 8:30 AM EST - 4 months ago

GeneDx to Participate in Upcoming Investor Conferences

Feb 23, 2026, 8:30 AM EST - 4 months ago

GeneDx Holdings Earnings Call Transcript: Q4 2025

Feb 23, 2026, 8:30 AM EST - 4 months ago

GeneDx Holdings Annual report: Q4 2025

Feb 23, 2026, 8:30 AM EST - 4 months ago

GeneDx Holdings Earnings release: Q4 2025

Feb 23, 2026, 8:30 AM EST - 4 months ago

GeneDx Holdings Slides: Q4 2025

Feb 23, 2026, 8:07 AM EST - 4 months ago

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

Feb 23, 2026, 6:30 AM EST - 4 months ago

GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

Feb 11, 2026, 9:05 AM EST - 5 months ago

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in Health

Feb 3, 2026, 8:00 AM EST - 5 months ago

GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

Jan 15, 2026, 11:24 AM EST - 6 months ago

Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

Jan 14, 2026, 6:00 PM EST - 6 months ago

GeneDx Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 6 months ago

GeneDx Holdings Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 3:03 PM EST - 6 months ago

Why is GeneDx stock crashing on Monday?

Jan 12, 2026, 7:30 AM EST - 6 months ago

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

Jan 8, 2026, 8:30 AM EST - 6 months ago

GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset

Jan 7, 2026, 8:30 AM EST - 6 months ago

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

Jan 6, 2026, 8:30 AM EST - 6 months ago

GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

Jan 5, 2026, 8:30 AM EST - 6 months ago

GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025

Dec 30, 2025, 8:00 AM EST - 6 months ago

GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 15, 2025, 8:30 AM EST - 7 months ago

JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year

Dec 11, 2025, 10:37 AM EST - 7 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY ASND INSM MASI NTRA PODD UNH

Dec 3, 2025, 1:30 PM EST - 7 months ago

GeneDx Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 6:00 AM EST - 8 months ago

GeneDx Holdings Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 2:00 PM EST - 8 months ago

GeneDx Holdings Transcript: Stifel 2025 Healthcare Conference

Nov 6, 2025, 8:00 AM EST - 8 months ago

GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

Oct 28, 2025, 8:30 AM EDT - 8 months ago

GeneDx Holdings Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

GeneDx Holdings Quarterly report: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

GeneDx Holdings Earnings release: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

GeneDx Holdings Slides: Q3 2025

Oct 28, 2025, 6:30 AM EDT - 8 months ago

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 27, 2025, 8:00 AM EDT - 8 months ago

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

Badinvestor50 Jul. 2 at 5:10 PM

$WGS down 5% on 360k in volume what a joke

0 · Reply

CarverX Jul. 1 at 8:11 PM

$WGS $TEM Good moves today in gene diagnostics 🚀🚀🚀

0 · Reply

11thestate Jun. 30 at 2:08 PM

0 · Reply

Buckanator Jun. 29 at 6:00 PM

$WGS I sold today at $68.95, Great trade, more than doubled my money.

2 · Reply

CarverX Jun. 29 at 5:04 PM

$WGS Probably 60s range bound til earnings

0 · Reply

Badinvestor50 Jun. 26 at 6:41 PM

$BSX $WGS well I jinxed these two that’s for sure

0 · Reply

Badinvestor50 Jun. 26 at 4:25 PM

$BSX rip missing $45. It’s alright this is going to move back like $WGS soon

0 · Reply

PencilNeckGeek Jun. 26 at 2:17 PM

$WGS Impressive how strong this has been

0 · Reply

CarverX Jun. 25 at 7:47 PM

$WGS Lots of insider purchases to buffet the sp and get the shyster lawyersboff our backs. Time for Stue to step up or time for Meister to get rid of her🚀🚀🚀

0 · Reply

PencilNeckGeek Jun. 25 at 7:26 PM

$WGS Pretty amazing strength this has shown recently

0 · Reply

CarverX Jun. 25 at 7:23 PM

$WGS Pushing thru 76.4% fib retracement of 65🚀🚀🚀

0 · Reply

stocksmit Jun. 25 at 1:51 PM

$WGS beautiful. With AI interpretation of genome data and sequencing. This thing is hopefully just starting its run.

0 · Reply

Buckanator Jun. 24 at 2:03 PM

$WGS Big time insider buying by the Director, off we go!

0 · Reply

11thestate Jun. 23 at 2:09 PM

$WGS / $SMFR Settlement Update: Sema4 Holdings has reached a tentative settlement with investors The case focused on claims that the company overstated the capabilities of Centrellis and the business benefits expected from the GeneDx transaction. Following this, $SMFR dropped over 33%, and the company faced a lawsuit from investors. Eligible investors may be able to submit a claim: https://11th.com/cases/sema4-investor-suit

0 · Reply

stocksmit Jun. 17 at 8:37 PM

$WGS odd sell off gift. These insiders absolutely buying the hell out of this. $75

0 · Reply

Badinvestor50 Jun. 17 at 7:14 PM

$WGS wow we had a bad day here. Two weeks of gains gone in a day. Just like everything else I own today

1 · Reply

11thestate Jun. 17 at 2:42 PM

You can still file a late claim in the $21 Million GeneDx ($WGS) settlement. The settlement claims that shareholders were misled in connection with the company's 2021 de-SPAC merger and were not given all material information needed to make an informed decision about whether to redeem their shares. Investors who held shares between July 2021 and July 2021 may still be eligible to file a claim: https://11th.com/cases/cmls-investor-settlement

0 · Reply

Jasooon Jun. 16 at 2:26 PM

$WGS You don't hire executives unless you are confident in growth.

2 · Reply

MaverikIT Jun. 15 at 2:55 PM

$WGS $TEM @Jblack500 @No_Face_character @BustaCapital @cynicaloptimist @IsabellaDC @WAJeff

1 · Reply

Jasooon Jun. 13 at 8:22 PM

$WGS Another huge insider purchase, Casdin again. Something is brewing and insiders believe there is a huge disconnect in market price and intrinsic valuation.

0 · Reply

CarverX Jun. 12 at 4:56 PM

$WGS Fibonacci retracements 0% (b) 167 23.6% 135.612 38.2% 116.194 50% 100.5 61.8% 84.806 76.4% 65.388 100% (a) 34

0 · Reply

Buckanator Jun. 11 at 8:31 PM

$WGS yep still holding, no brainer purchase

0 · Reply

Market Cap	2.00B
Revenue (ttm)	427.54M
Net Income (ttm)	-21.02M
EPS (ttm)	N/A
PE Ratio	84.36
Forward PE	N/A
Profit Margin	-4.92%
Debt to Equity Ratio	0.38

Volume	925,800
Avg Vol	1,485,668
Day's Range	N/A - N/A
Shares Out	29.69M
Stochastic %K	70%
Beta	1.90
Analysts	Strong Sell
Price Target	$78.89